×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Biopharma Layoff Tracker 2024: BMS, CureVac, Tessera and More Cut Staff
BioSpace
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
5 minutes ago
Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB
Fierce Pharma
Joining a list that recently includes Pfizer, UCB and WuXi AppTec, Takeda Pharmaceuticals is the latest drugmaker to pull out of prominent...
10 hours ago
Takeda is fourth big company to leave BIO since December
STAT
WASHINGTON — Takeda Pharmaceuticals has left the biotechnology industry's main lobbying group, the fourth departure of a major member since...
2 days ago
Bristol, Sanofi, Takeda gain positive CHMP recommendations
Seeking Alpha
A European Medicines Agency advisory committee has issued positive opinions on treatments from Bristol-Myers Squibb, Sanofi, and Takeda.
3 hours ago
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for ...
PR Newswire
PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma...
4 days ago
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Fierce Pharma
Novartis is mitigating a potential threat from the BIOSECURE Act. A Neurocrine drug from Takeda posted a trial win. Enhertu nears a HER2-low...
12 hours ago
Takeda And Astellas Agree To Establish Joint Venture Company
Contract Pharma
New joint venture aims to cover the entire drug discovery process, spanning early drug discovery research through the inception of drug...
4 days ago
How Takeda harnessed the power of the metaverse for positive human impact
EY
EY teams launch a metaverse proof of concept supporting employee immersive learning and collaboration, in just four months. Facebook · Twitter · LinkedIn...
1 week ago
Takeda inks sweet $1.2B-plus immuno-oncology deal with Kumquat
Fierce Biotech
Takeda is offering Kumquat the chance to make $1.2-plus billion in a pact that centers around an unnamed immuno-oncology small-molecule...
1 week ago
FDA Approve Takeda's Crohn's Disease Therapy
European Pharmaceutical Manufacturer
Takeda have announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO (vedolizumab) subcutaneous administration for...
4 days ago